AAPL - Apple Inc.
JANX
Janux Therapeutics, Inc.
13.80
10 x 13.74
10 x 13.87
bid
ask
+
0.24
1.77%
10 @ 08:27 AM
13.05 -0.75 (5.43%)
Ytd 0.00%
1y -55.24%
13.68
day range
14.10
12.12
52 week range
35.34
Open 13.73 Prev Close 13.56 Low 13.68 High 14.10 Mkt Cap 839.48M
Vol 1.24M Avg Vol 1.36M EPS -1.83 P/E N/A Forward P/E -9.91
Beta 2.82 Short Ratio 6.19 Inst. Own 110.14% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 05-07 50-d Avg 13.72 200-d Avg 21.03 1yr Est 76.71
Earning
Date For Estimate Reported Surprise surprise %
2025-11-06 2025-09 0 N/A 0.21 35.00%
2025-08-07 2025-06 0 N/A -0.07 -14.58%
2025-08-07 2025-06 0 N/A N/A N/A
2025-05-08 2025-03 0 N/A 0.05 11.63%
2025-05-08 2025-03 0 N/A N/A N/A
2025-02-27 2024-12 0 N/A N/A N/A
Upgrade / Downgrade
Date Firm Action From To
2025-12-02 Stifel Upgrade Buy Buy
2025-12-02 Clear Street Upgrade Buy Buy
2025-12-02 B of A Securities Upgrade Buy Buy
2025-12-02 Cantor Fitzgerald Upgrade Overweight Overweight
2025-12-02 HC Wainwright & Co. Upgrade Buy Buy
2025-11-25 HC Wainwright & Co. Upgrade Buy Buy
Profile
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Insider Holder
Date Name Relation Quantity Description
2025-06-10 BARRETT RONALD W Director 6.25K Stock Award(Grant)
2025-06-10 CAPPS VICKIE LYNN Director 74.10K Stock Award(Grant)
2025-06-10 DOBMEIER ERIC L Director 9.98K Stock Award(Grant)
2025-06-10 GUJRATHI SHEILA Director 118.89K Stock Award(Grant)
2025-06-10 HERNDAY NATASHA A Director 8.73K Stock Award(Grant)
2025-06-10 KUNG WINSTON Director 6.25K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2025-09-29 RA Capital Management, L.P. 11.19M 177.47M 18.60%
2025-09-29 FMR, LLC 9.06M 143.63M 15.06%
2025-09-29 Janus Henderson Group PLC 4.70M 74.56M 7.82%
2025-09-29 Blackrock Inc. 3.73M 59.17M 6.20%
2025-09-29 Paradigm Biocapital Advisors LP 2.92M 46.32M 4.86%
2025-09-29 Adage Capital Partners GP L.L.C. 2.78M 44.01M 4.61%
Fund Ownership
Report Date Organization Position Value Percentage
2025-09-29 Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund 1.44M 22.85M 2.39%
2025-09-29 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 1.18M 18.65M 1.96%
2025-09-29 Fidelity Select Portfolios-Select Health Care Portfolio 1.03M 16.38M 1.72%
2025-09-29 SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF 978.54K 15.52M 1.63%
2025-09-29 iShares Trust-iShares Russell 2000 ETF 983.28K 15.59M 1.63%
2025-08-30 Fidelity Securities Fund-Fidelity Small Cap Growth Fund 694.52K 11.02M 1.15%